VCM
JAZZ icon

Vigilant Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Vigilant Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-27
Closed -$4K – 697
2021
Q3 		$4K Buy
+27
New +$4.08K ﹤0.01% 700

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vigilant Capital Management's JAZZ Position: Q4 2021 in Review

Vigilant Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2021, closing a stake of 27 shares — an estimated $4K sold.

Vigilant Capital Management first reported a position in JAZZ in Q3 2021 and held it in 1 quarter. The position peaked at $4K in Q3 2021. 454 funds tracked by Wall St. Rank hold JAZZ as of Q4 2021.

  • Vigilant Capital Management reported no remaining Jazz Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Vigilant Capital Management sold 27 Jazz Pharmaceuticals shares in Q4 2021, an estimated $4K.
  • Vigilant Capital Management first reported a position in Jazz Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Vigilant Capital Management's Jazz Pharmaceuticals position peaked at $4K in Q3 2021.
  • 454 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2021.

Based on Vigilant Capital Management's 13F filing for Q4 2021, filed 6 Jan 2022.